SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Air pollution might be playing an increasing role in causing the disease.

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Aloe vera has anti-inflammatory properties that can help soothe and heal the oesophageal lining damaged by acid reflux. In ...

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 ...

Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...